Tuberculosis is one of the leading global causes of mortality, and it is believed that one third of the population has a latent case of the disease. Pretomanid is a therapy for treatment of tuberculosis, and was recently approved by the US FDA under the Limited Population Pathway (LPAD Pathway) for treatment of pulmonary extensively drug resistant (XDR) tuberculosis in combination with bedaquiline and linezolid. It works as a respiratory poison against bacteria by releasing nitric oxide under anaerobic conditions.